BIO-TECHNE Corp (TECH) stock
TECHNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends June 30
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K/A on Oct 28, 2026Score 12/3038% above fair value
$72.66−0.05 (-0.07%)
Close on Oct 30, 2026Market cap $11.39BP/E 62.6Yield 0.44%
Earnings
Bio-Techne's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Nov 4, 2026
Q1 FY2027 · estimated, before the open
Revenue, Q4 FY2026
$321.20M
+1.3% on a year earlier
Adjusted EPS, Q4 FY2026
$0.52
$0.53 a year earlier
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of Bio-Techne's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q1 FY2027ended Sep 30, 2026 | Nov 4, 2026Expected | – | – | – | – | – |
| Q4 FY2026ended Jun 30, 2026 | Aug 12, 2026before the open | $321.20M | +1.3% | $0.35 | $0.52 | Release |
| Q3 FY2026ended Mar 31, 2026 | May 6, 2026before the open | $311.40M | -1.5% | $0.32 | $0.53 | Release |
| Q2 FY2026ended Dec 31, 2025 | Feb 4, 2026before the open | $295.90M | -0.4% | $0.24 | $0.46 | Release |
| Q1 FY2026ended Sep 30, 2025 | Nov 5, 2025before the open | $286.60M | -1.0% | $0.24 | $0.42 | Release |
| Q4 FY2025ended Jun 30, 2025 | Aug 6, 2025before the open | $317.00M | +3.6% | -$0.11 | $0.53 | Release |
| Q3 FY2025ended Mar 31, 2025 | May 7, 2025before the open | $316.20M | +4.2% | $0.14 | $0.56 | Release |
| Q2 FY2025ended Dec 31, 2024 | Feb 5, 2025before the open | $297.00M | +9.0% | $0.22 | $0.42 | Release |
| Q1 FY2025ended Sep 30, 2024 | Oct 30, 2024before the open | $289.50M | +4.6% | $0.21 | $0.42 | Release |
| Q4 FY2024ended Jun 30, 2024 | Aug 7, 2024before the open | $306.10M | +1.6% | $0.25 | $0.49 | Release |
| Q3 FY2024ended Mar 31, 2024 | May 1, 2024before the open | $303.40M | – | $0.31 | $0.48 | Release |
| Q2 FY2024ended Dec 31, 2023 | Feb 1, 2024before the open | $272.60M | +0.4% | $0.17 | $0.40 | Release |
| Q1 FY2024ended Sep 30, 2023 | Oct 31, 2023before the open | $276.90M | +2.7% | $0.31 | $0.41 | Release |
| Q4 FY2023ended Jun 30, 2023 | Aug 8, 2023before the open | $301.30M | – | $0.47 | $0.55 | Release |
| Q3 FY2023ended Mar 31, 2023 | May 3, 2023before the open | – | – | – | – | Filing |
| Q2 FY2023ended Dec 31, 2022 | Feb 2, 2023before the open | $271.60M | +0.9% | $0.31 | $0.47 | Release |
| Q1 FY2023ended Sep 30, 2022 | Nov 1, 2022before the open | $269.70M | +4.7% | $2.21 | $1.78 | Release |
| Q4 FY2022ended Jun 30, 2022 | Aug 4, 2022before the open | – | – | – | – | Filing |
| Q3 FY2022ended Mar 31, 2022 | May 4, 2022before the open | $290.40M | – | $1.48 | $2.14 | Release |
| Q2 FY2022ended Dec 31, 2021 | Feb 1, 2022before the open | $269.30M | – | $1.94 | $1.88 | Release |
| Q1 FY2022ended Sep 30, 2021 | Nov 2, 2021before the open | $257.70M | – | $1.69 | $1.83 | Release |
| Q4 FY2021ended Jun 30, 2021 | Aug 5, 2021before the open | – | – | – | – | Release |
| Q3 FY2021ended Mar 31, 2021 | May 6, 2021before the open | – | – | – | – | Release |
| Q2 FY2021ended Dec 31, 2020 | Feb 2, 2021before the open | – | – | – | – | Release |
| Q1 FY2021ended Sep 30, 2020 | Nov 5, 2020before the open | – | – | – | – | Release |
| Q4 FY2020ended Jun 30, 2020 | Aug 4, 2020before the open | – | – | – | – | Release |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Bio-Techne has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Bio-Techne puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Bio-Techne filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Results
- Results
- Update
- Results
- Results
- News
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results